News and FDA-Alerts

The case study, accompanied by a review of 17 similar reports, details shared immunopathogenesis and conflicting treatment responses in this rare overlap syndrome.

The study evaluated treatment patterns and patient characteristics to assess the impact of these guidelines in real-world care.

The findings suggest that thyroid abnormalities may represent an independent comorbidity, rather than a direct consequence of psoriasis severity.

A new multi-method analysis challenges long-standing concerns regarding beta-blockers and their role in triggering or worsening psoriasis.

A new cross-sectional study comparing early-onset and late-onset psoriasis highlights key clinical and psychosocial differences that may inform individualized care strategies for dermatologists.

Psoriasis is traditionally understood as a T cell–mediated disease, driven largely by Th1 and Th17 cell activation and impaired regulatory T cell (T-reg) function.

By incorporating comorbidity surveillance into dermatologic care, clinicians can improve disease control, minimize therapeutic risks, and enhance overall patient quality of life.

For practicing dermatologists, these findings reinforce current guidelines that position TNF inhibitors as a first-line biologic option for patients with active psoriatic arthritis.

As the understanding of psoriasis pathophysiology continues to evolve, treatment goals may need to expand accordingly.